Fate Therapeutics (FATE)
(Delayed Data from NSDQ)
$5.41 USD
-0.03 (-0.55%)
Updated Jul 29, 2024 04:00 PM ET
After-Market: $5.41 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Brokerage Reports
Fate Therapeutics, Inc. [FATE]
Reports for Purchase
Showing records 401 - 420 ( 441 total )
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Positive PUMA Interim Readout and Steering the Fate of Adoptive T-Cell Therapies
Provider: H.C. WAINWRIGHT & CO., INC.
Analyst: BENJAMIN R
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q4:14 EPS: Pivotal Year of Data Readouts Ahead for FATE, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
4Q14 Update-Multiple Trials Fated for 2015 Readout
Provider: H.C. WAINWRIGHT & CO., INC.
Analyst: BENJAMIN R
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events from the Week of March 9th
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
ProHema Passes Second Interim Review in PUMA, Awaiting Final Data in Mid-15, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
LIFE SCIENCES AND HEALTH CARE-The Week Ahead in Life Sciences - Upcoming Events for the Week of Dec 15
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology/Biopharmaceuticals/BioDefense-Recap of American Society for Hematology Meeting (ASH) 2014 Presentations
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
ASH 2014 Highlights From Days 1-2-More than CARs and Checkpoints
Provider: H.C. WAINWRIGHT & CO., INC.
Analyst: BENJAMIN R
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Nov 17
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q3:14, Data-Rich 2015, Exciting Preclinical Data for ProHema in Peripheral Blood to be Presented at ASH, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Nov 10
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Oct 13
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Sept 22
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Recent Novartis Investment in Gamida Cell Points to FATE Shares as Undervalued, Reiterate Outperform
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Recent Novartis Investment in Gamida Cell Points to FATE Shares as Undervalued, Reiterate Outperform
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q2:14, Interim PUMA Review Shows Improved ProHema Formulation is Safe, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D